Lineage Cell Therapeutics (LCTX) Cash & Equivalents Growth (1y) (2011 - 2026)
Lineage Cell Therapeutics (LCTX) Cash & Equivalents Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 23.81% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 15.53% |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 90.42% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 17.50% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -4.13% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 71.81% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 254.83 Mn | 192.11 Mn | 1.73 Mn | -5.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.45% |
| Dec 31, 2025 | 12.06% |
| Sep 30, 2025 | 16.11% |
| Jun 30, 2025 | 42.70% |
| Mar 31, 2025 | 9.89% |
| Dec 31, 2024 | 37.02% |
| Sep 30, 2024 | -11.83% |
| Jun 30, 2024 | -12.58% |
| Mar 31, 2024 | 182.03% |
| Dec 31, 2023 | 163.63% |
| Sep 30, 2023 | 27.16% |
| Jun 30, 2023 | -52.18% |
| Mar 31, 2023 | -80.21% |
| Dec 31, 2022 | -79.63% |
| Sep 30, 2022 | -59.30% |
| Jun 30, 2022 | 14.28% |
| Mar 31, 2022 | 38.88% |
| Dec 31, 2021 | 71.07% |
| Sep 30, 2021 | 86.73% |
| Jun 30, 2021 | 389.12% |